Over the previous few years, the Well being Care & Life Sciences and Progressive Expertise Sectors have seen fewer offers, with corporations and personal fairness companies alike reassessing the place to spend cash. However one portion of the business is bucking this development in a significant method. Since 2018, licensing offers totaling over $60 billion have been signed relating to Antibody Drug Conjugates (ADCs), with 2023 alone having at the very least 18 offers. Because of this, worldwide ADC gross sales are projected to achieve $20-30 billion per yr within the close to future.
We welcome you to Antibody Conjugates Preserve Rising: What You Have to Know. On this eBook, our authors reply your authorized and enterprise questions referring to the speedy growth of ADCs and the way you and your group can perceive ADCs, whether or not it’s pharmaceutical transactions, FDA/regulatory, mental property, scientific trial, or litigation considerations. This eBook is designed to supply the information and insights wanted to reach the ADC business.
Desk of Contents
1. Antibody Drug Conjugates: An FDA Perspective
2. Methods For Patenting Antibody-Drug Conjugate Innovations
3. Offers and Licensing for Antibody-Drug Conjugates
4. Antibody-Drug Conjugate Litigation
5. Scientific Trial Points for Antibody Drug Conjugates/Antibody Therapeutics
The publish Antibody Drug Conjugates Preserve Rising: What You Have to Know appeared first on Foley & Lardner LLP.